Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $52.70 +1.50 (2.93%) 8:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AMAG Pharmaceuticals Focuses on Product Development & Buyouts

We issued an updated report on AMAG Pharmaceuticals, Inc. (AMAG) on Jul 4.

    Pfizer's (PFE) Leukemia Candidate Receives Approval in EU

    Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.

      The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

      The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva

        Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US

        Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.

          Arpita Dutt headshot

          Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

          Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

            Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

            Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

              Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy

              The pharma and biotech industry has been blessed with good health in the first half of the year.

                Seattle Genetics (SGEN) Reports Positive Data for Adcetris

                Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

                  Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU

                  Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.

                    Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion

                    Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion recommending marketing approval of a pediatric formulation of Mimpara for the treatment of secondary hyperparathyroidism

                      Regeneron (REGN) Stock on Fire: What's Behind the Surge?

                      Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.

                        Why You Should Add Novo Nordisk Stock to Your Portfolio

                        Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

                          Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

                          Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.

                            Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

                            Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).

                              Horizon Pharma Gets Health Canada Approval for Procysbi

                              Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

                                Arpita Dutt headshot

                                4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio

                                The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.

                                  Sanofi: Should Value Investors Consider SNY Stock?

                                  Value investing is easily one of the most popular ways to find great stocks in any market environment.

                                    Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

                                    Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

                                      Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

                                      Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

                                        Seres Therapeutics' Stock Up as SER-109 Moves to Phase III

                                        Shares of Seres Therapeutics, Inc. (MCRB) went up by more than 5% on Monday, after it announced that its lead pipeline candidate, SER-109, has moved into late-stage development for the treatment of multiply recurrent C. difficile infection.

                                          Intercept (ICPT) Releases Data from Phase II Flint Trial

                                          Intercept Pharmaceuticals, Inc. (ICPT) announced a retrospective analysis of the phase II trial, FLINT, in patients who were diagnosed with nonalcoholic steatohepatitis (NASH) and type II diabetes.

                                            Valeant Inks Deal to Divest iNova Pharmaceuticals for $930M

                                            Valeant Pharmaceuticals International, Inc. (VRX) announced that it has signed a deal to sell iNova Pharmaceuticals for $930 million in cash to a company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group.

                                              Ryan McQueeney headshot

                                              3 Large Cap Pharma Stocks to Buy Now

                                              Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!

                                                Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

                                                Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

                                                  Is the Options Market Predicting a Spike in Sanofi (SNY) Stock?

                                                  Investors in Sanofi (SNY) need to pay close attention to the stock based on moves in the options market lately.